董監事
| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| BRITISH ANGUILLA SHANG XIA DING INVESTMENT CO., LTD. | Chairman | 4.44% | |
| Panlabs Biologics Inc. | Vice Chairman | 4.11% | |
| Li,Dong-Yang | Director | 3.70% | |
| Qiu,Jing-Zhen | Director | 1.53% | |
| AN RUI MANAGEMENT CONSULTANT LTD. | Director | 0.00% | |
| Li,Yu-Ping | Supervisor | 0.00% | |
| Zhang,Hong-Ru | Supervisor | 1.63% |
公司歷程
Change Company Name to Protect Biotech Incorporation
2024/04/02
Change Capital to 2,000,000,000
2023/08/30
Change Capital to 300,000,000
2023/02/03
Change Company Name to BAOTAI BIOMEDICAL CO., LTD. (FORMER NAME: BAOTAI BIOMEDICAL CO., LTD.)
2021/11/18
Change Capital to 21,500,000
2021/03/23
Change Capital to 15,000,000
2020/12/21
Change Capital to 13,745,000
2020/12/09
Change Capital to 7,170,000
2020/10/20
Change Person in Charge to Song,Hao-Lin
2020/10/20
Change Company Name to Protect Biotech Incorporation
2020/04/20
員工人數
下載完整報告查看完整數據
財務報表
| 項目 | 2025 |
|---|---|
| Operating income | 8,185 |
| Operating cost | 4,401 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - |
| Operating gross profit (loss) | 3,784 |
| Unrealized profit (loss) on sales of goods | - |
| Realized profit (loss) on sales of goods | - |
| Operating gross profit (loss), net | 3,784 |
| Operating expenses | 116,432 |
| Other gain (loss), net | - |
| Operating profit (loss) | -112,648 |
| Non-operating income and expenses | -25,685 |
| Net profit (loss) before tax | -138,333 |
| Income tax expense (benefits) | -6,803 |
| Net profit (loss) of ongoing business for the current period | -131,530 |
| Profit (loss) of closed units | - |
| Profit (loss) of non-jointly controlled equity before merger | - |
| Net profit (loss) for the current period | -131,530 |
| Other comprehensive profit (loss), net | -1,866 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - |
| Total comprehensive profit and loss for the current period | -133,396 |
| Net profit (loss) attributable to owners of parent company | -131,530 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - |
| Net profit (loss) attributable to non-controlling interests | - |
| Comprehensive profit (loss) attributable to owners of parent company | -133,396 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - |
| Basic earnings per share (yuan) | -1 |
| 項目 | 2025 |
|---|---|
| Net cash inflow (outflow) from operating activities | -109,771 |
| Net cash inflows (outflows) from investing activities | -264,268 |
| Net cash inflow (outflow) from financing activities | 342,910 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | -7,184 |
| Increase (decrease) in cash and cash equivalents in the current period | -38,313 |
| Beginning balance of cash and cash equivalents | 277,677 |
| Ending balance of cash and cash equivalents | 239,364 |
| 項目 | 2025 |
|---|---|
| Current asset | 1,056,843 |
| Non-current asset | 115,546 |
| Total asset | 1,172,389 |
| Current liability | 42,662 |
| Non-current liability | 27,428 |
| Total liability | 70,090 |
| share capital | 976,588 |
| Equity - secruity token | - |
| capital reserve | 415,095 |
| retained earning | -288,686 |
| Other equity | -698 |
| Treasury stock | - |
| Total equity attributable to owners of parent company | 1,102,299 |
| Equity attributable to former owner of business combination under common control | - |
| Equity attributable to non-controlling interest before business merger under common control | - |
| Non-controlling interests | - |
| Total Equity | 1,102,299 |
| Share capital awaiting retirement (unit: share) | - |
| Issued shares of advance equity (unit: shares) | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 |
| Net asset value per share | 11 |
